B

종근당홀딩스

001630KOSPI

59.0 / 100

Reference Date: 2026-10-23

Financial Score32.5 / 40
News Sentiment12.5 / 25
Momentum7.0 / 20
Disclosure7.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but Revenue metrics are weak. Declined 7.5% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

JonggeunDang Holdings became a holding company through a corporate split in 2013, owning key subsidiaries such as JonggeunDang, Kyungbo Pharmaceuticals, and JonggeunDang Bio. Its primary revenue streams include management fees, brand usage fees, and dividends, with a strategy focused on specialized business areas to enhance corporate and shareholder value. Major subsidiaries operate in diverse sectors like raw pharmaceutical materials, finished drugs, and health functional foods.

Number of Employees

38people

Average Salary

143.6M KRW

Score Calculation Basis

Detailed Financial Score

PER
4.20Industry Average 15.008.0Point

Half of industry avg (excellent)

PBR
0.20Industry Average 1.207.0Point

Half of industry avg (excellent)

ROE
6.16Industry Average 8.002.5Point

Below industry avg

Debt Ratio
10.95Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20257.0 / 10 points
Revenue Growth Rate
1.0 / 3

Avg ▲4.5% (2-year basis)

Operating Profit Growth Rate
3.0 / 3

Avg ▲86.5% (2-year basis)

ROE Trend
3.0 / 4

Avg ROE 5.3% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 35,650Won52-week high 53,70052-week low 35,650
1-month return1.0Point

1m -7.52% (falling)

Volume trend5.0Point

Volume increasing

Detailed Disclosure

3 totalPositive 0Neutral 2Negative 1
  • Neutral[기재정정]반기보고서 (2026.06)2026-10-12
  • Negative[기재정정]주요사항보고서(영업정지)(자회사의 주요경영사항)2026-09-30
  • Neutral주식등의대량보유상황보고서(일반)2026-09-30